loading
Schlusskurs vom Vortag:
$47.66
Offen:
$47.33
24-Stunden-Volumen:
1.20M
Relative Volume:
0.56
Marktkapitalisierung:
$3.71B
Einnahmen:
$170.10M
Nettoeinkommen (Verlust:
$-239.59M
KGV:
-16.71
EPS:
-2.8
Netto-Cashflow:
$-191.20M
1W Leistung:
+5.41%
1M Leistung:
+27.06%
6M Leistung:
+14.03%
1J Leistung:
-17.30%
1-Tages-Spanne:
Value
$45.60
$47.55
1-Wochen-Bereich:
Value
$43.23
$48.48
52-Wochen-Spanne:
Value
$30.04
$63.68

Crispr Therapeutics Ag Stock (CRSP) Company Profile

Name
Firmenname
Crispr Therapeutics Ag
Name
Telefon
(617) 315-4600
Name
Adresse
BAARERSTRASSE 14, ZUG
Name
Mitarbeiter
393
Name
Twitter
@crisprtx
Name
Nächster Verdiensttermin
2024-12-05
Name
Neueste SEC-Einreichungen
Name
CRSP's Discussions on Twitter

Vergleichen Sie CRSP mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
CRSP
Crispr Therapeutics Ag
46.81 3.71B 170.10M -239.59M -191.20M -2.80
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
444.17 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
519.92 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
316.63 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
560.50 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
260.15 28.51B 3.81B -644.79M -669.77M -6.24

Crispr Therapeutics Ag Stock (CRSP) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-02-14 Hochstufung Evercore ISI In-line → Outperform
2025-02-12 Hochstufung TD Cowen Sell → Hold
2025-02-03 Eingeleitet H.C. Wainwright Buy
2024-08-06 Bestätigt Needham Buy
2024-08-02 Eingeleitet Rodman & Renshaw Buy
2024-06-28 Fortgesetzt Guggenheim Neutral
2024-02-15 Eingeleitet Wolfe Research Peer Perform
2023-12-11 Herabstufung TD Cowen Market Perform → Underperform
2023-10-17 Herabstufung Cantor Fitzgerald Overweight → Neutral
2023-09-27 Eingeleitet Mizuho Buy
2023-08-17 Hochstufung Citigroup Neutral → Buy
2023-05-30 Eingeleitet William Blair Outperform
2023-04-13 Eingeleitet Cantor Fitzgerald Overweight
2023-03-21 Eingeleitet Bernstein Mkt Perform
2023-03-17 Eingeleitet Bryan Garnier Buy
2023-03-07 Eingeleitet Robert W. Baird Neutral
2022-10-11 Eingeleitet Morgan Stanley Underweight
2022-08-09 Herabstufung Barclays Overweight → Equal Weight
2022-06-23 Herabstufung Evercore ISI Outperform → In-line
2022-06-17 Eingeleitet BMO Capital Markets Outperform
2022-04-28 Eingeleitet Credit Suisse Neutral
2021-12-07 Eingeleitet Cowen Market Perform
2021-10-19 Eingeleitet SVB Leerink Outperform
2021-06-14 Hochstufung Citigroup Sell → Neutral
2021-04-21 Hochstufung Jefferies Hold → Buy
2021-03-04 Eingeleitet JMP Securities Mkt Outperform
2020-12-10 Bestätigt Chardan Capital Markets Buy
2020-12-10 Herabstufung Jefferies Buy → Hold
2020-12-10 Bestätigt Needham Buy
2020-12-07 Herabstufung Wells Fargo Overweight → Equal Weight
2020-10-23 Eingeleitet RBC Capital Mkts Sector Perform
2020-10-05 Eingeleitet BofA Securities Buy
2020-07-28 Bestätigt Needham Buy
2020-07-14 Eingeleitet SunTrust Buy
2020-06-15 Bestätigt Canaccord Genuity Buy
2020-03-05 Eingeleitet Stifel Hold
2020-02-03 Herabstufung Evercore ISI Outperform → In-line
2019-11-19 Hochstufung William Blair Mkt Perform → Outperform
2019-11-12 Hochstufung Oppenheimer Perform → Outperform
2019-08-01 Eingeleitet Jefferies Buy
2019-07-26 Eingeleitet Canaccord Genuity Buy
2019-06-10 Eingeleitet ROTH Capital Buy
2019-04-12 Eingeleitet Evercore ISI Outperform
2019-03-14 Eingeleitet William Blair Mkt Perform
2019-01-28 Herabstufung Goldman Buy → Neutral
2019-01-22 Herabstufung Citigroup Neutral → Sell
Alle ansehen

Crispr Therapeutics Ag Aktie (CRSP) Neueste Nachrichten

pulisher
Jun 18, 2025

CRISPR Therapeutics AG (CRSP) Increases Despite Market Slip: Here's What You Need to Know - Yahoo Finance

Jun 18, 2025
pulisher
Jun 18, 2025

Traders Buy High Volume of Call Options on CRISPR Therapeutics (NASDAQ:CRSP) - MarketBeat

Jun 18, 2025
pulisher
Jun 18, 2025

CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It - MSN

Jun 18, 2025
pulisher
Jun 18, 2025

From Now to 2032: Unpacking the Genome Editing Market's - openPR.com

Jun 18, 2025
pulisher
Jun 18, 2025

CRISPR Therapeutics’ SWOT analysis: gene editing pioneer’s stock faces pivotal year - Investing.com

Jun 18, 2025
pulisher
Jun 18, 2025

Gene-Editing Stocks Gain on LLY-VERV Deal Announcement - Yahoo

Jun 18, 2025
pulisher
Jun 18, 2025

Citizens JMP reiterates CRISPR Therapeutics stock rating on in-vivo progress - Investing.com

Jun 18, 2025
pulisher
Jun 18, 2025

SG Americas Securities LLC Grows Position in CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat

Jun 18, 2025
pulisher
Jun 17, 2025

CRISPR Therapeutics (NASDAQ:CRSP) Shares Gap UpShould You Buy? - MarketBeat

Jun 17, 2025
pulisher
Jun 17, 2025

Editas Medicine Is Great. Here's Why You Shouldn't Buy It. - The Motley Fool

Jun 17, 2025
pulisher
Jun 16, 2025

25,341 Shares in CRISPR Therapeutics AG (NASDAQ:CRSP) Purchased by Avanza Fonder AB - MarketBeat

Jun 16, 2025
pulisher
Jun 15, 2025

Can a $10,000 Investment in CRISPR Therapeutics Turn Into $1 Million? - 24/7 Wall St.

Jun 15, 2025
pulisher
Jun 14, 2025

Millennium Management LLC Trims Stock Holdings in CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat

Jun 14, 2025
pulisher
Jun 14, 2025

Equities Analysts Set Expectations for CRSP FY2026 Earnings - MarketBeat

Jun 14, 2025
pulisher
Jun 14, 2025

Crispr extends gains for the seventh consecutive trading day - MSN

Jun 14, 2025
pulisher
Jun 13, 2025

Crispr Therapeutics: Betting On A One-Shot Future (NASDAQ:CRSP) - Seeking Alpha

Jun 13, 2025
pulisher
Jun 13, 2025

Trend Tracker for (CRSP) - news.stocktradersdaily.com

Jun 13, 2025
pulisher
Jun 13, 2025

CRISPR Therapeutics (NASDAQ:CRSP) Trading Up 6%Here's What Happened - MarketBeat

Jun 13, 2025
pulisher
Jun 13, 2025

Crispr Therapeutics AG: Stock Soars Amid Bullish Trends - MSN

Jun 13, 2025
pulisher
Jun 11, 2025

CRISPR Therapeutics Gains 14% in a Month: How to Play the Stock? - Yahoo Finance

Jun 11, 2025
pulisher
Jun 11, 2025

Crispr Therapeutics: Early-Stage Research Updates Show Promise (NASDAQ:CRSP) - Seeking Alpha

Jun 11, 2025
pulisher
Jun 11, 2025

Cantor Fitzgerald Weighs in on CRSP FY2026 Earnings - Defense World

Jun 11, 2025
pulisher
Jun 10, 2025

CRISPR Therapeutics AG (CRSP) Rises Higher Than Market: Key Facts - Yahoo Finance

Jun 10, 2025
pulisher
Jun 10, 2025

Crispr Therapeutics (CRSP) Rallies Amid FDA Fast-Tracking News - GuruFocus

Jun 10, 2025
pulisher
Jun 10, 2025

Crispr extends gains for the seventh consecutive trading day (CRSP:NASDAQ) - Seeking Alpha

Jun 10, 2025
pulisher
Jun 09, 2025

CRISPR Therapeutics AG shareholders approve key proposals By Investing.com - Investing.com South Africa

Jun 09, 2025
pulisher
Jun 09, 2025

CRISPR Therapeutics AG Shareholders Approve Key Proposals - TipRanks

Jun 09, 2025
pulisher
Jun 09, 2025

CRISPR Therapeutics AG shareholders approve key proposals - Investing.com

Jun 09, 2025
pulisher
Jun 09, 2025

Cathie Wood Just Flagged The Start Of A Biotech Revolution: These 2 Stocks With 10x Potential Are Leading It - Benzinga

Jun 09, 2025
pulisher
Jun 09, 2025

Wealth Enhancement Advisory Services LLC Has $1.08 Million Stake in CRISPR Therapeutics AG (NASDAQ:CRSP) - Defense World

Jun 09, 2025
pulisher
Jun 08, 2025

Investors Heavily Search CRISPR Therapeutics AG (CRSP): Here is What You Need to Know - MSN

Jun 08, 2025
pulisher
Jun 07, 2025

CRISPR Therapeutics (NasdaqGM:CRSP) Sees 16% Stock Price Surge Over Last Month - simplywall.st

Jun 07, 2025
pulisher
Jun 05, 2025

Crispr: Shares Very Undervalued, as Early-Stage Pipeline Makes Progress and Casgevy Launch Underway - Morningstar

Jun 05, 2025
pulisher
Jun 05, 2025

CRSP Sees Significant Increase in Bullish Option Activity | CRSP Stock News - GuruFocus

Jun 05, 2025
pulisher
Jun 05, 2025

Crispr Therapeutics call volume above normal and directionally bullish - TipRanks

Jun 05, 2025
pulisher
Jun 05, 2025

CRISPR Therapeutics (CRSP) Up 11.1% Since Last Earnings Report: Can It Continue? - Yahoo Finance

Jun 05, 2025
pulisher
Jun 05, 2025

CRISPR Therapeutics AG (NASDAQ:CRSP) Stake Raised by Green Alpha Advisors LLC - MarketBeat

Jun 05, 2025
pulisher
Jun 04, 2025

Can CRISPR Build on Casgevy's Success With Its In Vivo Pipeline? - sharewise

Jun 04, 2025
pulisher
Jun 03, 2025

Promising Growth and Diversification Drive Buy Rating for Crispr Therapeutics AG - TipRanks

Jun 03, 2025
pulisher
Jun 03, 2025

Can CRISPR Build On Casgevy's Success With Its In Vivo Pipeline? - Barchart.com

Jun 03, 2025
pulisher
Jun 03, 2025

CRISPR Therapeutics AG (NASDAQ:CRSP) Shares Sold by Voloridge Investment Management LLC - MarketBeat

Jun 03, 2025
pulisher
Jun 03, 2025

Capital Market Strategies LLC Buys 9,652 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat

Jun 03, 2025
pulisher
Jun 03, 2025

Q2 EPS Forecast for CRISPR Therapeutics Increased by Analyst - MarketBeat

Jun 03, 2025

Finanzdaten der Crispr Therapeutics Ag-Aktie (CRSP)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Crispr Therapeutics Ag-Aktie (CRSP) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
Kulkarni Samarth
Chief Executive Officer
Mar 21 '25
Sale
41.23
10,031
413,578
195,085
Bruno Julianne
Chief Operating Officer
Mar 21 '25
Sale
41.23
1,714
70,668
10,544
Prasad Raju
Chief Financial Officer
Mar 21 '25
Sale
41.23
2,197
90,582
16,767
KASINGER JAMES R.
General Counsel and Secretary
Mar 21 '25
Sale
41.23
3,185
131,318
81,729
Prasad Raju
Chief Financial Officer
Mar 17 '25
Sale
41.80
3,762
157,252
12,714
Kulkarni Samarth
Chief Executive Officer
Mar 11 '25
Sale
42.42
9,973
423,055
180,890
Kulkarni Samarth
Chief Executive Officer
Mar 12 '25
Sale
43.32
4,462
193,294
185,428
KASINGER JAMES R.
General Counsel and Secretary
Mar 11 '25
Sale
42.42
2,850
120,897
77,530
KASINGER JAMES R.
General Counsel and Secretary
Mar 12 '25
Sale
43.32
1,116
48,345
78,664
Bruno Julianne
Chief Operating Officer
Mar 11 '25
Sale
42.42
1,198
50,819
8,263
$20.61
price up icon 0.78%
$36.03
price up icon 0.39%
$21.65
price up icon 1.34%
$105.24
price up icon 0.02%
$104.98
price up icon 0.19%
biotechnology ONC
$264.93
price down icon 1.26%
Kapitalisierung:     |  Volumen (24h):